Hi — I handle bulk & wholesale for this oil. Ask me anything, or tap a question below.
What the research says
More than a carrier. And we cite every word.
People reach for Tamanu for more than one thing. Here’s what the published studies actually found — graded honestly, each one linked.
11
uses studied
12
papers cited
0
hidden from you
What the published studies found
Early evidence · 2 studies
Hair Loss/Thinning
Evidence for tamanu (Calophyllum inophyllum) in hair loss is limited to in-vitro studies showing that leaf extracts (not the nut-derived oil itself) stimulated dermal papilla cell proliferation, with glycosylated flavonols and phenolic acids identified as candidate bioactives. Traditional Polynesian use for hair care is documented, but no animal studies or human clinical trials exist.
The only identifiable evidence is a single in vitro study showing Calophyllum inophyllum (tamanu) seed oil has antioxidant activity (DPPH/ABTS assays) and tyrosinase inhibition, with the authors noting relevance to 'aging-related health concerns' only speculatively. No human clinical trials, in vivo skin studies, or wrinkle-specific outcomes exist for tamanu oil.
The primary identifiable evidence is an in vitro study (PMID 26406588) showing that Calophyllum inophyllum (tamanu) oils from five origins accelerated keratinocyte wound closure by 1.3–2.1x versus control at 0.1% concentration and exhibited antibacterial activity against both Gram+ and Gram- bacteria (including MRSA), supporting traditional use for infected wounds. However, no human clinical trials, RCTs, or controlled studies were identifiable in the provided results, so evidence remains preclinical only.
A single in vitro study (PMID 26406588) found that Calophyllum inophyllum (tamanu) oil accelerated keratinocyte wound closure (1.3–2.1x vs. control) and exhibited antibacterial activity against Gram+ and Gram- bacteria, including S. aureus—a pathogen relevant to eczema flares. However, eczema is only referenced as a traditional use; no clinical trials, animal eczema models, or human studies have tested tamanu oil for eczema specifically.
The only retrievable study tested tamanu oil as one of five essential oils incorporated into levan/bentonite biodegradable food-packaging films and measured in-vitro antimicrobial activity, including against Candida albicans; notably, the strongest antifungal effect (40 mm inhibition zone) came from peppermint oil, not tamanu. No human, animal, or clinical studies evaluating tamanu oil for fungal infection were found in this result set.
The only relevant study found is an ethnobotanical survey documenting that non-institutionally trained Siddha practitioners in Tamil Nadu use Calophyllum inophyllum (tamanu) externally for musculoskeletal complaints, with headache showing high informant consensus among externally applied formulations. No clinical trials, in-vivo efficacy studies, or mechanistic research on tamanu oil for headache or migraine were identified.
The only identifiable relevant study (PMID 38256935) is a preclinical formulation study showing tamanu oil bigels improved wound healing and scar reduction in a rat excision model, supported by in silico docking to TGF-β1; hyperpigmentation is mentioned only as part of traditional-use background and was never directly measured. No human clinical trials, RCTs, or studies directly assessing pigmentation outcomes (e.g., melanin index, melasma, or post-inflammatory hyperpigmentation) were found.
The only directly relevant evidence is a preclinical rat study (PMID 27593261) showing ethanol extracts of Calophyllum inophyllum stem bark and seeds reduced paw oedema by 28.6% and 36.4% respectively in Freund's adjuvant-induced arthritis (vs 43.5% for diclofenac), supported by in vitro anti-inflammatory assays and histological/radiological findings. No human clinical trials, RCTs, or systematic reviews exist for tamanu oil in joint inflammation, and the study tested ethanol extracts rather than the oil itself.
No clinical studies directly evaluate tamanu oil for muscle pain. The most relevant publication identified (PMID 35069754) is a narrative review on atopic dermatitis that cites in vitro and in vivo evidence of analgesic and anti-inflammatory properties, offering only indirect, preclinical support for pain-related use.
The only relevant study is a 2023 in vitro metabolomic analysis of five Polynesian plants including Calophyllum inophyllum (tamanu), which showed antioxidant activity in DPPH/FRAP/TPC assays; psoriasis was mentioned only as background context linking oxidative stress to skin pathology, no direct anti-psoriatic testing was performed, and tamanu was not the most active extract (Ficus prolixa was). No clinical trials, RCTs, or case studies of tamanu oil for psoriasis were found, though traditional Polynesian use for skin conditions is documented.
Only one relevant study exists: a preclinical rodent study (PMID 26223138) showing that an ethanol leaf extract of Calophyllum inophyllum produced sedative-like effects in behavioral tests (reduced head dips, reduced rearing/grooming). No human trials, no direct sleep/insomnia outcomes, and no studies on the seed oil itself (commercial tamanu oil) were found.
